SAN DIEGO, April 12, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced the establishment of a Named Patient Program for SUMAVEL ® DosePro ® (sumatriptan injection) Needle-free ...
Please provide your email address to receive an email when new articles are posted on . A low dose of sumatriptan provided significantly higher 2-hour pain freedom and 2-hour pain relief vs. placebo, ...
Sumavel(TM) DosePro(TM) (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System SAN DIEGO, July 16 ...
SCHAUMBURG, Ill., Aug. 2 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced two FDA approvals -- sumatriptan succinate injection and ...
SAN DIEGO, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders ...
“With the approval and launch of sumatriptan injection, we remain optimistic on progress of our other combination product development programs with Teva, which are currently under FDA review.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback